Related Experiment Video
Updated: Sep 20, 2025

External Cephalic Version: Is it an Effective and Safe Procedure?
Published on: June 6, 2020
Prophylactic Oral Cephalexin and Metronidazole Compared With Placebo After Cesarean Delivery to Reduce Infection
Antonio F Saad1, Brett Goldman, Nicholas Spencer
1Division of Maternal-Fetal Medicine, Inova Health, Falls Church, and the Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia; the Division of Maternal-Fetal Medicine, TriHealth, Cincinnati, Ohio; Austin Maternal-Fetal Medicine, St. David's Women's Center of Texas, Austin, Texas; and the Division of Maternal-Fetal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Objective:
To compare prophylactic oral cephalexin and metronidazole with placebo for 48 hours after cesarean delivery following membrane rupture on the frequency of composite infection morbidity postpartum among pregnant individuals with obesity.
Methods:
This randomized, double-blind clinical trial was conducted at two medical centers from August 2017 to August 2023. We enrolled women with obesity (pregnancy body mass index [BMI] 30 or higher) and ruptured membranes (for 4 hours or more) undergoing cesarean delivery who were also receiving standard intravenous preoperative prophylaxis with cefazolin and azithromycin. Participants were assigned randomly to receive either oral cephalexin (500 mg) and metronidazole (500 mg) or an identical placebo every 8 hours for 48 hours after their cesarean delivery. The primary outcome was a composite of infection complications , defined as a composite of endometritis, surgical site infection, or other postcesarean infections (pelvic septic thrombosis, abdominal or pelvic abscess based on radiologic diagnosis) within 30 days after cesarean delivery. With an anticipated relative risk reduction of 50% and a two-sided α=.05 with 80% power and a 1:1 ratio of exposed to unexposed, a total sample size of 302 participants was planned to detect a reduction in the primary outcome from 25% in the placebo group to 12.5% in the antibiotic group.
Results:
Of the 321 women who were randomized (mean±SD age 27.5±6.1 years, mean±SD BMI 38.4±6.8), 160 received cephalexin-metronidazole and 161 received placebo with a total of 284 (88.5%) who completed the study per protocol. The overall rate of the composite infection outcome was 6.2% (95% CI, 3.8-9.5%). In the cephalexin-metronidazole group, 9 women (5.6%) developed the composite compared with 11 women (6.8%) in the placebo group (difference 1.2%, 95% CI, -2.5% to 5.0%; odds ratio 0.81, 95% CI, 0.33-2.02; P =.64). No serious adverse events, including allergic reactions, were reported in either group.
Conclusion:
In women with obesity undergoing cesarean delivery with an extended-spectrum preoperative antibiotic regimen that included azithromycin, the addition of a postoperative 48-hour course of oral cephalexin and metronidazole did not significantly lower the rate of infection complications within 30 days after delivery.
Clinical Trial Registration:
ClinicalTrials.gov , NCT03187106.
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Calculi IV: Nutrition Therapy and Prevention

